Advertisement

Adenosine Deaminase (ADA; E.C. no. 3.5.4.4.) in Colorectal Adenocarcinoma in Man

  • Joop ten Kate
  • Juul Th. Wijnen
  • Elly Herbschleb-Voogt
  • Gerrit Griffioen
  • Fred T. Bosman
  • P. Meera Khan
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 165)

Abstract

Soluble ADA is known to occur in different isozymes in man. Two major forms have been identified in the normal human tissues: the so called red cell ADA or ADA-S, a monomeric protein, with a M.W. of about 35KD (kilodaltons), and a tissue specific form, or ADA-L, of about 300KD, composed of a dimeric glycoprotein molecule (adenosine deaminase complexing protein=ADCP) and two molecules ADA-S. Additional ADA isozymes have been reported by several authors: a form of 435KD in the normal intestine, a so called particulate form in different tissues probably due to membrane bound ADA4 and a cancer specific 70KD in some colorectal tumors5. Nishihara et al.6 observed that free ADCP, usually present in normal lung tissue, was strongly decreased in the extracts of cancerous lung. Trotta and Balis presented evidence for the absence of ADCP in a clear cell carcinoma of the kidney, in spite of the fact that normal kidney is the major source of free ADCP. In the same report they described a striking decrease of ADA-L, thus of ADCP, in 14 out of 15 colorectal tumors. These data and the data presented by Herbschleb-Voogt et al. (this conference), where ADA-L was found to be almost absent or markedly decreased in 6 transformed- and tumor derived cell lines, formed the basis for the present investigation.

Keywords

Colorectal Tumor Colorectal Adenocarcinoma Adenosine Deaminase Clear Cell Carcinoma Normal Lung Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    PE Daddona, WN Kelley, Mol Cell Biochem, 29: 91 (1980)PubMedCrossRefGoogle Scholar
  2. 2.
    YH Edwards, DA Hopkinson, Ann Hum Genet, 35: 207 (1971)PubMedCrossRefGoogle Scholar
  3. 3.
    MB van der Weyden, WN Kelley, J Biol Chem, 251: 5448 (1976)PubMedGoogle Scholar
  4. 4.
    WP Schrader, PJ Bryer, Arch Biochem Bioph, 215: 107 (1982)CrossRefGoogle Scholar
  5. 5.
    PP Trotta, ME Balis, Biochemistry, 17: 270 (1978)PubMedCrossRefGoogle Scholar
  6. 6.
    H Nishihara, S Ishikawa, K Shinkai, H Akedo, Biochim Biophys Acta, 302: 429 (1973)PubMedCrossRefGoogle Scholar
  7. 7.
    Jten Kate, J Th Wijnen, E Herbschleb-Voogt, G Griffioen, FT Bosnian, P Meera Khan, in press, in: “Progress in Clin Enzymology, Vol 2”Google Scholar
  8. 8.
    PE Daddona, WN Kelley, J Biol Chem, 253: 4617 (1978)PubMedGoogle Scholar
  9. 9.
    BE Chechik, A Madapallimattam, EW Gelfand, J Natl Cancer Inst, 62: 465 (1979)PubMedGoogle Scholar
  10. 10.
    PE Daddona, MA Frohman, WN Kelley, J Clin Invest, 64: 98 (1979)CrossRefGoogle Scholar
  11. 11.
    OH Lowry, NJ Rosebrough, AL Farr, RJ Randall, J Biol Chem, 193: 265 (1951)PubMedGoogle Scholar
  12. 12.
    DA Hopkinson, PJL Cook, H Harris, Ann Hum Genet, 32: 361 (1969)PubMedCrossRefGoogle Scholar
  13. 13.
    FT Bosnian, JWK Louwerens, Am J Pathol, 104: 174 (1981)Google Scholar
  14. 14.
    LP Rutzky, MJ Siciliano, J Natl Cancer Inst, 68: 81 (1982)PubMedGoogle Scholar
  15. 15.
    WP Schrader, B Pollara, J Lab Clin Med, 92: 656 (1978)PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • Joop ten Kate
    • 1
  • Juul Th. Wijnen
    • 1
  • Elly Herbschleb-Voogt
    • 1
  • Gerrit Griffioen
    • 2
  • Fred T. Bosman
    • 3
  • P. Meera Khan
    • 1
  1. 1.Dept. of Human GeneticsUniversity of LeidenAL LeidenThe Netherlands
  2. 2.Dept. of Gastro EnterologyUniversity Medical CenterLeidenThe Netherlands
  3. 3.Dept. of PathologyBiomedical Center MaastrichtUSA

Personalised recommendations